Drug Profile
Granisetron intranasal - Maxinase Life Sciences
Alternative Names: Granisetron Hydrochloride Nasal Spray (GNS) - Maxinase Life SciencesLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Maxinase Life Sciences
- Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chemotherapy-induced nausea and vomiting
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for phase-I development in Chemotherapy-induced-nausea-and-vomiting(In volunteers) in Taiwan (Intranasal, Spray)
- 31 Dec 2015 Maxinase Life Sciences completes a phase I trial in Chemotherapy induced nausea and vomiting (In volunteers) in Taiwan (Intranasal) (NCT02563951)
- 16 Sep 2015 Maxinase Life Sciences plans a phase I trial in Healthy volunteers in Taiwan (NCT02563951)